How Un-POPular Is Bleeding in Patients with TAVI?

Abstract

For years, bleeding complications in patients undergoing transcatheter procedures, predominantly percutaneous coronary interventions (PCIs), were not included in the primary outcome of clinical trials. It was not until the REPLACE-2 (Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events 2) trial, which assessed two anticoagulant strategies for PCI, that bleeding became a component of the primary outcome and was found to be a predictor of death at 1 year that was as powerful as myocardial infarction.(1) As the population ages, increasing numbers of patients have indications for oral anticoagulants, either a vitamin K antagonist or direct-acting oral anticoagulants. Not . . .